UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation

Nature reviews. Genetics, 2008-02, Vol.9 (2), p.115-128

2008

Volltextzugriff (PDF)

Genome-wide Map of Nuclear Protein Degradation Shows NCoR1 Turnover as a Key to Mitochondrial Gene Regulation

Cell, 2013-12, Vol.155 (6), p.1380-1395

2013

Volltextzugriff (PDF)

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

Investigational new drugs, 2014-06, Vol.32 (3), p.481-488

2014

Volltextzugriff (PDF)

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

Xenobiotica, 2014-04, Vol.44 (4), p.352-368

2014

Volltextzugriff (PDF)

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4023-4031

2015

Volltextzugriff (PDF)

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

Clinical cancer research, 2021-09, Vol.27 (18), p.4994-5003

2021

Volltextzugriff (PDF)

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical cancer research, 2022-04, Vol.28 (8), p.1540-1548

2022

Volltextzugriff (PDF)

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Cancer chemotherapy and pharmacology, 2015-01, Vol.75 (1), p.183-189

2015

Volltextzugriff (PDF)

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial

Clinical cancer research, 2022-04, Vol.28 (8), p.1540-1548

2022

Volltextzugriff (PDF)

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours

British journal of clinical pharmacology, 2014-09, Vol.78 (3), p.524-532

2014

Volltextzugriff (PDF)

Differential H3K4 Methylation Identifies Developmentally Poised Hematopoietic Genes

Developmental cell, 2008-05, Vol.14 (5), p.798-809

2008

Volltextzugriff (PDF)

Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-Independent Growth, Anoikis, and Radiation-Induced Cell Cycle Arrest

The Journal of cell biology, 1999-08, Vol.146 (4), p.855-867

1999

Volltextzugriff (PDF)

Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma

Blood, 2015-12, Vol.126 (23), p.3059-3059

2015

Volltextzugriff (PDF)

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3005-3005

2017

Volltextzugriff (PDF)

Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia

Blood, 2015-12, Vol.126 (23), p.2566-2566

2015

Volltextzugriff (PDF)

Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer

Journal of clinical pharmacology, 2013-09, Vol.53 (9), p.946-954

2013

Volltextzugriff (PDF)

Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin

The Journal of biological chemistry, 1997-10, Vol.272 (40), p.24735-24738

1997

Volltextzugriff (PDF)

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.1011-1011

2016

Volltextzugriff (PDF)

Abstract 3094: Discovery of a HeliconTM peptide inhibitor of the beta-catenin-TCF interaction with in vivo activity

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3094-3094

2023

Volltextzugriff (PDF)

Abstract 4972: Anti-tumor activity of Helicon inhibitors of Β-catenin-TCF interaction in patient-derived xenograft models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4972-4972

2023

Volltextzugriff (PDF)

Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS9108-TPS9108

2014

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(57)
Dissertationen
(1)

Sprache

Englisch
(58)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation

Genome-wide Map of Nuclear Protein Degradation Shows NCoR1 Turnover as a Key to Mitochondrial Gene Regulation

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours

Differential H3K4 Methylation Identifies Developmentally Poised Hematopoietic Genes

Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-Independent Growth, Anoikis, and Radiation-Induced Cell Cycle Arrest

Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors

Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia

Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer

Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC)

Abstract 3094: Discovery of a HeliconTM peptide inhibitor of the beta-catenin-TCF interaction with in vivo activity

Abstract 4972: Anti-tumor activity of Helicon inhibitors of Β-catenin-TCF interaction in patient-derived xenograft models

Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma

Suchergebnisse filtern